- Patients must have a minimum of five, available unstained slides from the residual (post-neoadjuvant) invasive tumor in primary site or lymph node to be submitted within 7 days after registration to determine PD-L1 expression; the tumor tissue must be adequate for PD-L1 testing, which typically requires a minimum of 100 cancer cells per slide